# Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)

> **NCT06150898** · PHASE2 · RECRUITING · sponsor: **Jules Bordet Institute** · enrollment: 112 (estimated)

## Conditions studied

- Early-stage Breast Cancer
- Estrogen-receptor-positive Breast Cancer

## Interventions

- **PROCEDURE:** Prospective data and sample collection
- **DRUG:** Ketorolac 10 Mg Oral Tablet
- **DRUG:** Pregabalin 75mg
- **DRUG:** Omeprazole 20mg Capsule

## Key facts

- **NCT ID:** NCT06150898
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-12
- **Primary completion:** 2027-04-20
- **Final completion:** 2027-10
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2025-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06150898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06150898, "Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06150898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*